NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Incyte Corporation
Washington University School of Medicine
Daiichi Sankyo
Bristol-Myers Squibb
Georgetown University
Memorial Sloan Kettering Cancer Center
NYU Langone Health
Nektar Therapeutics
Nektar Therapeutics
Calithera Biosciences, Inc
Incyte Corporation
Bristol-Myers Squibb
Duke University
Dana-Farber Cancer Institute
Bristol-Myers Squibb
Northwestern University